By KEY TAKEAWAYS
- Brain-computer interfaces are real but medical: today's implants help people with severe paralysis control computers, and no one is buying a brain chip to speed up their inbox.
- Neuralink, Synchron and Precision Neuroscience take three different approaches, from deep in the brain to a stent in a vein to a film on the surface, with very different risk and regulatory profiles.
- For marketers, the near-term lesson is not 'advertise to thoughts' but accessibility and neural privacy: the interface changes slowly, and trust rules will arrive before the ads do.
Most of us spend our days translating thoughts into thumbs. Think a sentence, tap it out, fix the typo, repeat. A handful of companies would like to delete the middle step.
Brain-computer interfaces, or BCIs, read signals from your brain and turn them into computer commands. It sounds like a sci-fi trailer, and the hype does not help. But some of it is real, and some of it is already in people’s heads.
Here is the grounded version: three companies, three approaches, what has actually been shown, and what a marketer should do about a technology that is years from your customers but already attracting headlines.
How we wrote this: facts link to company announcements or reputable reporting. Our interpretation is labeled “Our read.” Where sources disagree, we say so. Dates are as of October 2026. This is not medical advice.
The short version
BCIs today are medical devices. They help people with severe paralysis control computers with their thoughts. There is no consumer brain chip you can buy, and none that has full regulatory approval for implanted paralysis use as far as we could verify. Treat anything promising “telepathy by next year” as ambition, not a plan.
How does a brain-computer interface actually work?
An electrode array picks up electrical activity from neurons, software learns which patterns mean “move left” or “click,” and a computer acts on them. The user imagines a movement; the system translates the signal into a cursor move or a selected key.
The hard parts are the same everywhere: getting signals that are strong and stable, keeping the device safe for years inside a body, and doing it without brain surgery that most people would never accept. The three companies below made different bets on that last point.
The three approaches, side by side
| Neuralink | Synchron | Precision Neuroscience | |
|---|---|---|---|
| Approach | Thin threads placed directly in brain tissue by a surgical robot | “Stentrode” delivered by catheter through a neck vein | Thin film electrode array laid on the brain’s surface |
| Invasiveness | Highest | Lowest (no open-brain surgery) | In between |
| Public regulatory milestone | Breakthrough Device designation for Blindsight (reported 2024) | First US FDA-approved IDE trial of a permanently implanted BCI | FDA clearance for Layer 7, up to 30 days (April 2025) |
| Stage | Clinical trials | Feasibility study completed; larger trial planning | Cleared for short-term clinical use |
Our read: “least invasive” and “most capable” pull in opposite directions. The deeper the electrodes, the richer the signal, and the higher the surgical stakes.
What has Synchron shown?
Synchron’s COMMAND study found no neurologic safety events over 12 months in six patients with severe paralysis. According to the company’s announcement in September 2024, it was the first US FDA-approved investigational device exemption trial of a permanently implanted BCI (Synchron via BusinessWire).
The Stentrode goes in through the jugular vein using a catheter, much like a heart stent, which is why it avoids opening the skull. Patients used brain-derived signals to carry out digital tasks. The results are company-reported and small, so read them as “promising feasibility,” not “solved.” We could not confirm whether a larger pivotal trial has started, so check the company’s latest news.
What has Precision Neuroscience shown?
In April 2025 the FDA cleared Precision’s Layer 7 Cortical Interface for implantation of up to 30 days. The device is a high-resolution electrode array that records, monitors and stimulates electrical activity on the brain’s surface (Precision Neuroscience).
It was reported as the first full FDA clearance for a company building a next-generation wireless BCI, though that framing comes from the company itself (MedTech Dive). Important nuance: a 30-day clearance is a stepping stone, useful for brain mapping in surgery. It is not a permanent implant approved for daily life.
What about Neuralink?
Neuralink is the loudest name and the hardest to pin down with numbers. It runs human trials of an implant that lets people with paralysis control computers, and it has pursued a vision-restoring device called Blindsight, which reportedly received FDA Breakthrough Device designation in 2024.
Here we have to be honest: participant counts and performance claims in secondary reporting conflict, and some record claims are not peer reviewed. We have left specific figures out on purpose. For the latest, read Neuralink’s own updates and any published trial data, and discount anything that cannot be traced back to one of those. A Breakthrough designation speeds up development and review. It is not approval.
What are the big open questions?
Safety over years, signal stability and who owns the data. Early results are encouraging, but a device that must work reliably inside a body for a decade faces tests that a 12-month study cannot answer.
Four questions we would watch before believing any timeline:
- Durability. Do signals stay clean as the brain and the implant settle against each other over years? Reports of electrode problems in early devices across the field are a reminder this is unsolved engineering.
- Independent evidence. Peer-reviewed results on larger groups, not just company announcements.
- Cost and access. Surgery, specialist teams and long-term support are expensive. Even a successful medical device may reach very few people at first.
- Neural privacy. Who owns brain-derived data, and can it be used for anything other than the patient’s care? Law is still catching up, and we would not bet on brands being given the benefit of the doubt.
Our read: the most useful habit is to ask of every BCI headline, “Is this a patient result, a lab result, or a promise?” Patient results move slowly. Promises move fast and often get quietly rewritten.
Where could this go in the long run?
If the technology matures, the first mainstream uses will be assistive: typing, speaking and controlling devices for people who cannot do so otherwise. That is a worthwhile outcome on its own, and it is where the evidence points today.
Beyond that is speculation, and we label it as such. Maybe, someday, healthy users choose a non-surgical headset for hands-free control. Maybe not. Either way the pattern we have seen with every new interface holds: first came the novelty, then the useful niche, then the mass market, and the brands that did well treated each stage honestly.
Reality check: promised vs shipped
| Claim you may hear | What is actually shown |
|---|---|
| “Brain chips for everyone soon” | Experimental devices in small trials, for serious medical conditions |
| “Telepathy” | Imagined movement translated to cursor or text commands |
| “FDA approved” | Often a clearance or designation, which is not the same as approval for permanent use |
| “Record-breaking speed” | Often company-reported and not yet peer reviewed |
Our read: the technology is advancing, and the honest timeline for healthy-user products is long. Anyone giving you a date is selling something.
What this means for your business: fear, gain, pain
Using our fear, gain and pain frame:
- Fear. Neural data is the most personal data there is. If this technology reaches consumers, regulators and customers will punish brands that treat it casually. Brands should expect strict privacy rules, not a free-for-all.
- Gain. The first real winners are accessibility-minded businesses. Products and websites that work smoothly with alternative input methods serve a real, underserved audience today, with no chip required.
- Pain. Nothing here changes your Q4 plan. The pain is distraction: speculative tech stories can pull attention from the unglamorous work that pays, like clear messaging and being findable in AI search.
Our read: marketing “to thoughts” is not a strategy, and the first brand to try it will end up as a cautionary tale. The input device will keep changing, from keyboards to voice to, eventually, maybe thought. The thing that does not change is whether someone trusts you enough to act on what you say.
Related reading on where interfaces are heading: the AI gadget wars, humanoid robots are coming, and our 2027 predictions.
What to do this week
- Run a 30-minute accessibility check on your top landing page: keyboard navigation, screen-reader labels, voice-control friendliness. It pays off with real customers now.
- Write a one-paragraph data-ethics stance for your brand: what customer data you collect and what you never will. Neural data is simply the extreme case.
- Set up an alert for “brain-computer interface” from primary sources (company blogs, FDA announcements) so you can separate trials from rumors quickly.
- Spend the real effort on discoverability. Whatever the interface, people will keep asking questions; make sure assistants can find and cite you. Our AI Marketing Stack is a good place to start.
- Add a personal take. What would you do if a customer could “type” with their thoughts tomorrow? Jot it down; it is a useful stress test of your product.
Frequently asked questions
What is a brain-computer interface?
+
A brain-computer interface, or BCI, reads electrical signals from the brain and translates them into commands for a computer, such as moving a cursor or selecting a word. Today's systems are medical devices tested mainly in people with severe paralysis, helping them communicate and control digital tools without moving.
Is Neuralink approved by the FDA for general use?
+
No. Neuralink's implants are being tested in clinical trials, not sold for general use. Its Blindsight vision device has received an FDA Breakthrough Device designation, which speeds up development and review but is not marketing approval. Check Neuralink's own updates for the latest participant numbers, which vary across reports.
How is Synchron different from Neuralink?
+
Synchron's Stentrode is delivered through a blood vessel in the neck using a catheter, so it needs no open-brain surgery. Neuralink places ultra-thin threads directly into brain tissue with a surgical robot. The vein approach is less invasive; direct implants can, in principle, capture richer signals.
Will brain chips replace keyboards and phones?
+
Not soon. Current devices are experimental medical tools for people with serious conditions, and any consumer use would need years of safety evidence and regulatory approval. Expect assistive uses first. Anything aimed at healthy users is speculation today, and timelines from company executives should be treated as ambitions, not forecasts.
What do brain-computer interfaces mean for marketing?
+
In the near term, mostly accessibility and privacy. Brands should make products usable by people who rely on alternative inputs, and watch emerging neural-data privacy laws. Marketing to thoughts is science fiction for now, and the trust risks of even trying are huge. Win attention the old way: by being useful.
Sources
- Synchron, Synchron Announces Positive Results from U.S. COMMAND Study of Endovascular Brain-Computer Interface (September 2024)
- Precision Neuroscience, Precision Neuroscience Receives FDA Clearance for High-Resolution Cortical Electrode Array (April 2025)
- MedTech Dive, Precision Neuroscience brain implant FDA cleared (April 2025)
WRITTEN BY
Junaid Mubashar
Founder of an AI-native growth agency. Junaid plans and runs full-funnel marketing (SEO and AI search, paid social, Google Ads) and builds the AI workflows and agents that automate it. Everything on this blog is tested with real campaigns before we recommend it.
🧰 The 2027 AI Marketing Stack
The 37 AI tools and 12 workflow recipes we use to run marketing for clients — organised by funnel stage.